Kunihiro K. Yamaoka

Kanagawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Timing of Recombinant Herpes Zoster Virus Vaccination Administration and JAK Inhibitor Initiation in Rheumatoid Arthritis: A Multicenter, Open-Label, Randomized Comparative Study.

Timing of Recombinant Herpes Zoster Virus Vaccination Administration and JAK Inhibitor Initiation in Rheumatoid Arthritis: A Multicenter, Open-Label, Randomized Comparative Study.

Journal: Annals of internal medicine

Published: July 20, 2026

Methotrexate and Malignancy in Rheumatoid Arthritis: Evidence, Risks, and Clinical Considerations.

Methotrexate and Malignancy in Rheumatoid Arthritis: Evidence, Risks, and Clinical Considerations.

Journal: Modern rheumatology

Published: May 27, 2026

Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity.

Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity.

Journal: Immunological medicine

Published: April 09, 2026

Comparative Safety Analysis of Targeted Synthetic and Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan.

Comparative Safety Analysis of Targeted Synthetic and Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan.

Journal: International journal of rheumatic diseases

Published: March 20, 2026

2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.

2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.

Journal: International journal of rheumatic diseases

Published: March 02, 2026

Predictive value of interferon regulatory factor 5 nuclear translocation in B cells for disease activity and flare in systemic lupus erythematosus: a prospective observational cohort study.

Predictive value of interferon regulatory factor 5 nuclear translocation in B cells for disease activity and flare in systemic lupus erythematosus: a prospective observational cohort study.

Journal: Modern rheumatology

Published: December 08, 2025

Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3-Year J-Post-Marketing Surveillance.

Risk Factors for Major Adverse Cardiovascular Events, Malignancies, and Serious Infections With Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of a 3-Year J-Post-Marketing Surveillance.

Journal: International journal of rheumatic diseases

Published: October 03, 2025

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Journal: Rheumatology and therapy

Published: September 06, 2025

The Impact of Exercise Tolerance Assessed by 6-Min Walking Distance on Clinical Outcomes in Patients With Interstitial Lung Disease Associated With Connective Tissue Diseases.

The Impact of Exercise Tolerance Assessed by 6-Min Walking Distance on Clinical Outcomes in Patients With Interstitial Lung Disease Associated With Connective Tissue Diseases.

Journal: International journal of rheumatic diseases

Published: August 26, 2025

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.

Journal: RMD open

Published: August 05, 2025

Alternation of anti-NMDA receptor subunit GluN2 antibody in a patient with SLE who promptly developed anxiety after belimumab.

Alternation of anti-NMDA receptor subunit GluN2 antibody in a patient with SLE who promptly developed anxiety after belimumab.

Journal: Immunological medicine

Published: June 02, 2025

Safety and Efficacy of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE) for Mild COVID-19: A Double-Blind, Placebo-Controlled, Randomized Comparative Trial.

Safety and Efficacy of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE) for Mild COVID-19: A Double-Blind, Placebo-Controlled, Randomized Comparative Trial.

Journal: Microorganisms

Published: February 28, 2025

Showing 1-12 of 161

Last Updated: 09/26/2026